Baxter (NYSE:BAX) said today that it closed its $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz.
According to the deal, Baxter gains Claris’ portfolio of injectable generics and three manufacturing plants. The Deerfield, Ill.-based company said it plans to add new aseptic manufacturing and lyophilization capabilities, as well as invest in new technology platforms, including cytotoxics.
Get the full story at our sister site, Drug Delivery Business News.
The post Baxter closes Claris Injectables buy appeared first on MassDevice.
from MassDevice http://ift.tt/2uFFt8Q
Cap comentari:
Publica un comentari a l'entrada